Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-086702
Filing Date
2025-06-16
Accepted
2025-06-16 16:05:08
Documents
1
Period of Report
2025-06-13

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3855
  Complete submission text file 0000950170-25-086702.txt   5348
Mailing Address C/O ZENTALIS PHARMACEUTICALS, LLC 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018
Business Address
Blackwell Kimberly (Reporting) CIK: 0001816465 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40522 | Film No.: 251050040

Mailing Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118
Business Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118 617-949-2643
Monte Rosa Therapeutics, Inc. (Issuer) CIK: 0001826457 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)